B8F.DE Biofrontera AG XETRA trades €6.80 on heavy intraday volume: analyst view
B8F.DE stock surged intraday on 23 Feb 2026, trading at €6.80 on XETRA with volume of 45,797.00 shares versus an average of 605.00. The intraday range opened at €0.37 and hit a high of €6.80, leaving a day low of €0.30 and a recorded change of €6.48 (2000.00%). This high-volume move reflects a tiny free float—3,038,430.00 shares outstanding—and a sharp rel. volume of 75.70, conditions that amplify price swings and make short-term trading riskier. We break down valuation, fundamentals, Meyka AI grade, and a model forecast to help intraday and swing traders.
Intraday volume spike: B8F.DE stock trading activity
Today on XETRA B8F.DE stock traded €6.80 with volume 45,797.00, well above the 605.00 average and a rel. volume of 75.70. The stock opened at €0.37 and previous close was €0.32, producing a one-day move of 2000.00% and a top intraday range of €0.30–€6.80. The combination of low shares outstanding (3,038,430.00) and thin historical liquidity explains the quick, large price swing and the sharp gap between day low and high.
B8F.DE stock technicals and valuation snapshot
Technicals show the 50-day average at €6.53 and the 200-day average at €9.19, leaving the price slightly above the near-term trend but below the long-term average. Valuation metrics: market cap €20,673,478.00, P/E -32.40, EPS -0.21, price-to-sales 0.64, and price-to-book 21.73. Enterprise value to EBITDA is 3.36, which can signal a low relative enterprise valuation, but margin and profitability must improve before a re-rating is sustainable.
Earnings, cash flow and balance sheet for B8F.DE stock
Recent trailing metrics show operating cash flow per share -0.03 and free cash flow per share -0.04, while cash per share is 0.05 and book value per share is 0.31. The current ratio is 1.76 and debt-to-equity is 0.06, indicating limited leverage. Net profit margin is about -1.14%, and interest coverage is 318.80, reflecting low interest burden. These figures highlight modest liquidity but persistently negative profitability and cash conversion challenges.
Meyka AI rates and forecast for B8F.DE stock
Meyka AI rates B8F.DE with a score out of 100: Score 62.53 | Grade B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, industry peers, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €8.50, versus the current €6.80, implying an upside of 25.00%. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.
Risks and opportunities for B8F.DE stock
Key risks: extreme intraday volatility from a small free float, clinical or regulatory setbacks in dermatology products, and valuation inconsistency (year high €22.58, year low €0.30). Opportunities: niche dermatology products like Ameluz and Xepi, an existing partnership with Maruho, low EV/EBITDA 3.36 suggesting recovery potential, and current sector context where healthcare averages show muted YTD performance. Monitor company news and volume confirmation before adding exposure.
Trading strategy and watchlist signals for B8F.DE stock
For high-volume movers, trade size should be small and stops tight given the historic price swing and low shares outstanding. Watch the 50-day €6.53 and 200-day €9.19 averages for trend confirmation, and require above-average volume on follow-through moves. Use limit orders, set maximum position sizes, and check updates on the company site and our page: Biofrontera on Meyka. Also follow official disclosures at the company site: Biofrontera investor relations and Biofrontera homepage.
Final Thoughts
Intraday action on 23 Feb 2026 put B8F.DE stock in the spotlight: price €6.80 on volume 45,797.00 versus an average 605.00 shows extreme trading interest and potential short-term opportunity. Fundamentals are mixed — low leverage and respectable current ratio (1.76) contrast with negative EPS (-0.21) and weak free cash flow per share (-0.04). Meyka AI’s model projects a 12-month target of €8.50, an implied upside of 25.00%, but that assumes clinical and revenue progress. For traders, confirm moves with sustained volume above 605.00 and monitor the 50-day (€6.53) and 200-day (€9.19) averages. Remember, the Meyka grade (B, 62.53) is informational and not investment advice. Use strict risk controls and follow company disclosures on the official site before trading.
FAQs
Why did B8F.DE stock spike intraday today?
B8F.DE stock spiked due to heavy volume of 45,797.00 versus average 605.00, a tiny free float of 3,038,430.00 shares, and wide intraday price range. Small floats amplify moves; verify news or filings before trading.
What is Meyka AI’s price target for B8F.DE stock?
Meyka AI’s forecast model projects a 12-month target of €8.50 for B8F.DE stock, implying an upside of 25.00% versus €6.80. Forecasts are model-based projections and not guarantees.
Is B8F.DE stock a buy for short-term traders?
B8F.DE stock offers short-term volatility but elevated risk due to low liquidity and past price swings. Use small sizes, strict stops, and volume confirmation. This is not investment advice; do your own research.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.